How to present myself as a Chinese company in an appealing way on the European market?
Germany's medical economy is continuously growing. The medical technology sector alone generated sales of 30 billion euros in 2017, with an export quota of 64%, making it the third largest in the world. The DxPx Conference 2019 will be the world's first networking event for Dx stakeholders during the launch of MEDICA. In Düsseldorf, one of the largest metropolises in North Rhine-Westphalia (NRW), we expect investors, entrepreneurs and representatives from industry. The region is well known to the local people among them. The federal state of Germany, which is historically the most strongly represented in terms of population and economic yield, is an industrial hot spot and still produces a variety of innovations in the area of Research & Development (R&D) in large corporations, but above all small and medium-sized enterprises (SMEs) (93% Germany-wide according to the industry association BVMed), as well as universities. With its wealth of investments, on the one hand due to the high supply of capital by private investors and business angels, on the other hand due to its openness to equity capital, it is still one of the major market players within Germany and beyond its borders. Against the background of high trend awareness, the life science sector receives special attention from foreign investors. Biotechnology in particular is very popular in NRW. Throughout Europe, the region represents an additional major pharmaceutical location, a pulsating market for life science products and can be described as a leader in this sector with regard to the German start-up scene, alongside the flourishing founding stronghold of Berlin. China is also booming in the same area. In the medical technology industry alone, the global market share was 6% in 2017, but its growth curve is estimated at 26% until 2026, which is second place in the world rankings (1st place USA). This would mean a market volume of around 170 billion euros. If one considers the current expenditures within the entire health care system up to 2020, investments should amount to more than one trillion euros. Many of these capital expenditures have also flowed to Germany, where there are current investments in the market segments of clinics, health products/medical technology, biotechnology and pharmaceuticals. Germany is therefore a lucrative market – also for Chinese companies.